Actinium Pharmaceuticals Inc (ATNM) |
|
10.89 -0.07 (-0.64%)
|
11-27 00:48 |
|
Open: |
11.05 |
Pre. Close: |
10.96 |
|
High:
|
11.1 |
Low:
|
10.7 |
|
Volume:
|
328,696 |
Market Cap:
|
148M |
|
|
|
|
Actinium Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant or adoptive cell therapies. Its lead product candidate is Iomab-B, which is in a pivotal Phase III clinical trial as an induction and conditioning agent in patients over the age of 55 with relapsed or refractory acute myeloid leukemia prior to receiving a bone marrow transplant, also known as a hematopoietic stem cell transplant. The company is also developing Actimab-A, its lead alpha-particle drug candidate that is in a Phase II trial for patients newly diagnosed with AML age 60 and over; and Actimab-M, a drug candidate, for the treatment of patients with penta refractory multiple myeloma in a Phase 1 clinical trial. Its Antibody Warhead Enabling technology platform is currently being utilized in a research collaboration with Astellas Pharma, Inc. The company was founded in 2000 and is based in New York, New York. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
11.131 - 11.193 |
11.193 - 11.243 |
|
Low:
|
10.531 - 10.618 |
10.618 - 10.688 |
|
Close:
|
10.761 - 10.891 |
10.891 - 10.996 |
|
Technical analysis |
as of: 2020-11-25 4:35:46 PM |
|
Overall:
|
 |
| Stoxline posted a SELL today, same as yesterday. Downward movement continues. |
| Target: |
Six months: 13.83 One year: 15.40 |
| Support: |
Support1: 9.67 Support2: 8.05 |
| Resistance: |
Resistance1: 11.84 Resistance2: 13.18 |
| Pivot: |
11.46  |
| Moving Average: |
MA(5): 11.04 MA(20): 11.17 
MA(100): 11.03 MA(250): 8.82 |
| MACD: |
MACD(12,26): 0.13 Signal(9): 0.25 |
| Stochastic oscillator: |
%K(14,3): 22.50 %D(3): 31.88 |
| RSI: |
RSI(14): 47.33 |
| 52-week: |
High: 19.47 Low: 4.71 Change(%): 34.4 |
| Average Vol(K): |
3-Month: 34584 10-Days: 45792 |
|
Price, moving averages and Bollinger Bands |
|
Price and moving averages has closed below its Short term moving average. Short term moving average is currently above mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.ATNM has closed above bottom band by 21.9%. Bollinger Bands are 57.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to ATNM's normal range. The bands have been in this narrow range for 3 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Headline News |
Thu, 26 Nov 2020
Now Is The Time To Build A Position In Actinium Pharmaceuticals, Inc. (NYSE:ATNM) - Marketing Sentinel
Tue, 17 Nov 2020
Actinium Pharmaceuticals Inc (ATNM) Stock: What Does the Chart Say? - InvestorsObserver
Mon, 16 Nov 2020
Actinium to Participate in the Alliance Global Partners' Virtual Healthcare Symposium - PRNewswire
Fri, 13 Nov 2020
Actinium Pharmaceuticals (ATNM) Gains But Lags Market: What You Should Know - Nasdaq
Thu, 12 Nov 2020
Actinium Pharmaceuticals (ATNM) Receives a Buy from H.C. Wainwright - Smarter Analyst
Mon, 09 Nov 2020
Actinium Pharmaceuticals Inc (ATNM) Stock: Is It a Good Pick? - InvestorsObserver
|
Financial Analysis |
| Growth |
 |
| Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing. |
| Profitability |
 |
| Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs. |
| Solvency |
|
| Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry. |
| Efficiency |
n/a |
| Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not. |
| Price to Book Value: |
Outperform |
Discounted cash flow: |
Outperform |
| Return on Assets: |
Neutral |
Price to Earnings: |
Underperform |
| Return on Equity: |
Neutral |
Debt to Equity: |
Neutral |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: AMEX |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. (M) |
14 |
| Shares Float (M) |
12 |
|
% Held by Insiders
|
0.90 |
|
% Held by Institutions
|
13.90 |
|
Shares Short (K)
|
597 |
|
Shares Short P. Month (K)
|
390 |
Stock Financials |
|
EPS
|
-3.060 |
|
EPS Est This Year
|
-0.400 |
|
EPS Est Next Year
|
-0.250 |
|
Book Value (p.s.)
|
3.860 |
|
Profit Margin
|
|
|
Operating Margin
|
|
|
Return on Assets (ttm)
|
-34.8 |
|
Return on Equity (ttm)
|
-64.7 |
|
Qtrly Rev. Growth
|
|
|
Gross Profit (p.s.)
|
|
|
Sales Per Share
|
|
|
EBITDA (p.s.)
|
-1.560 |
|
Qtrly Earnings Growth
|
|
|
Operating Cash Flow (M)
|
-21 |
|
Levered Free Cash Flow (M)
|
-13 |
Stock Valuations |
|
PE Ratio
|
-3.56 |
|
PEG Ratio
|
|
|
Price to Book value
|
2.82 |
|
Price to Sales
|
|
|
Price to Cash Flow
|
-7.06 |
Stock Dividends |
|
Dividend
|
|
|
Forward Dividend
|
|
|
Dividend Yield
|
|
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
